Optimum’s clients continued to gain momentum in March, starting things off on Monday with a substantial financing agreement for Heidelberg Pharma, with HealthCare Royalty for up to $115 million. On Wednesday, Heidelberg followed this with the announcement that it is to present first efficacy data from a Phase 1 clinical trial with ATAC candidate HDP-101. […]
2023 was an exciting year for Optimum’s clients who overcame many of the market challenges to make significant strides forward with their vital life sciences research. Here are some of the highlights from what has been an exceptionally busy and successful year. M&A & deals Synaffix continued to build momentum – Lonza acquired the […]
UCB’s expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity™, will aid Ariceum’s discovery of treatments for solid tumors Ariceum’s expertise in radiopharmaceuticals and labelling technology will aid UCB’s discovery of treatments for immune-related diseases Potential to expand Ariceum’s pipeline with three new programs at discovery stage Berlin, Germany, and Brussels, Belgium, 11 […]
Find out what sets Ariceum Therapetutics apart within the radiopharmaceutical arena in this insightful interview with its CEO Manfred Rüdiger and Tyler Patchen of Endpoint News
Oversubscribed financing co-led by HealthCap and EQT Life Sciences (formerly LSP); joined by Pureos Bioventures Developing novel drugs for systemic targeted radiation therapy (STRT) Proceeds will be used to advance lead radiopharmaceutical product, satoreotide, for the treatment of neuroendocrine cancers and certain other aggressive, hard-to-treat cancers Led by industry veteran Manfred Rüdiger as CEO, and world-renowned […]
